ArticleCell death & disease2026
CircBRWD3 promotes non-small cell lung cancer progression through enhancing the stability of TRIM25 to increase p53 ubiquitin degradation and upregulating SPTBN2.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Circular RNAs (circRNAs) play crucial roles in cancer progression and metastasis. However, the expression profiles and biological roles of circRNAs in non-small cell lung cancer (NSCLC) remain unclear. In this study, we found a novel circRNA, hsa_circ_0001936(circBRWD3), in NSCLC and investigated the biological role of circBRWD3 in NSCLC progression in vitro and in vivo. qRT-PCR was used to quantify the expression of circBRWD3 in NSCLC tissues, serum and cells. Cell growth curves, colony formation, Edu assay and transwell assays were conducted to study the function of circBRWD3. Finally, the molecular mechanism of circBRWD3 was revealed by Bioinformatic analyses, RNA pull-down analysis, RNA Fluorescence in situ hybridization (FISH), RNA-Binding Protein Immunoprecipitation (RIP), western blot, dual-luciferase reporter gene assays and rescue experiments. Our results showed that circBRWD3 was upregulated in NSCLC tumor tissues, patient serum and cell lines. CircBRWD3 knockdown inhibited NSCLC cells' growth and metastasis both in vitro and in vivo, while circBRWD3 overexpression had the opposite effect. Mechanistically, circBRWD3 binds to the TRIM25 protein to enhance its stability and mediate ubiquitin degradation of the p53 protein. In addition, circBRWD3 acted as a sponge for miR-135a-5p and miR-135b-5p to regulate the expression of SPTBN2, which promoted NSCLC progression. Our findings uncovered a tumor oncogenic function of circBRWD3 in NSCLC through the regulation of TRIM25 protein stability and miR-135a-5p/miR-135b-5p/SPTBN2 axis. CircBRWD3 may act as a promising oncogenic biomarker and therapeutic target for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.